| 1 | 10146 | LAO-CT018 | ETCTN | Breast Cancer | Active | Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients with Metastatic Triple Negative Breast Cancer | II | 48/70 | N/A | INTERVENTION |
| 2 | 10273 | LAO-CA043 | ETCTN | Leukemia | Active | A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia | I | 39/48 | N/A | INTERVENTION |
| 3 | 10292 | LAO-NCI | ETCTN | Solid Tumor | Active | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination with Chemotherapy in Patients with Advanced Solid Tumors | II | 78/115 | N/A | INTERVENTION |
| 4 | 10299 | LAO-NCI | ETCTN | Lymphoma;Solid Tumor | Active | A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients | I | 1/95 | N/A | INTERVENTION |
| 5 | 10301 | LAO-CT018 | ETCTN | Male Reproductive System Cancer | Active | A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | I/II | 30/105 | N/A | INTERVENTION |
| 6 | 10504 | LAO-NCI | ETCTN | Soft Tissue Cancer/Sarcoma | Active | A Phase 2 Study of Atezolizumab with Selinexor in Alveolar Soft Part Sarcoma (AXIOM) | II | 10/77 | N/A | INTERVENTION |
| 7 | 10505 | LAO-CA043 | ETCTN | CNS Cancer (Primary tumor) | Active | A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma | I/II | 40/84 | N/A | INTERVENTION |
| 8 | 10507 | LAO-MA036 | ETCTN | Miscellaneous and Metastatic Cancer | Active | A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT Carcinoma | I/II | 18/18 | N/A | INTERVENTION |
| 9 | 10579 | LAO-PA015 | ETCTN | Gastrointestinal Cancer;Solid Tumor | Active | Phase I Trial of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors | I | 13/30 | N/A | INTERVENTION |
| 10 | 10603 | LAO-MA036 | ETCTN | Male Reproductive System Cancer | Active | A Phase 2 Study of M1774 in Refractory SPOP-Mutant Prostate Cancer | II | 9/17 | N/A | INTERVENTION |
| 11 | 10612 | LAO-CT018 | ETCTN | Myeloma | Active | A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma | II | 19/70 | N/A | INTERVENTION |
| 12 | 10629 | LAO-MD017 | ETCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined with Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer | I/II | 0/9 | N/A | INTERVENTION |
| 13 | 10630 | LAO-PA015 | ETCTN | Leukemia | Temporarily Closed to Accrual | Phase 1 Trial of Iadademstat in Combination with Venetoclax and Azacitidine in Patients with Treatment Naive AML | I | 2/45 | N/A | INTERVENTION |
| 14 | A021806 | ALLIANCE | NCTN | Gastrointestinal Cancer | Active | A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer | III | 311/352 | N/A | INTERVENTION |
| 15 | A021901 | ALLIANCE | NCTN | Endocrine Cancer | Active | Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors | II | 22/108 | N/A | INTERVENTION |
| 16 | A032102 | ALLIANCE | NCTN | Male Reproductive System Cancer | Active | PREcision DIagnostics in Prostate Cancer Treatment (PREDICT) | II | 2/474 | N/A | INTERVENTION |
| 17 | A041703 | ALLIANCE | NCTN | Leukemia | Active | A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease | II | 64/64 | N/A | INTERVENTION |
| 18 | A051902 | ALLIANCE | NCTN | Lymphoma | Active | A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas | II | 92/182 | N/A | INTERVENTION |
| 19 | A071401 | ALLIANCE | NCTN | CNS Cancer (Primary tumor) | Active | Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations | II | 90/124 | 503 | SCREENING, INTERVENTION |
| 20 | A072201 | ALLIANCE | NCTN | CNS Cancer (Primary tumor) | Temporarily Closed to Accrual | Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients with Recurrent Glioblastoma | II | 6/184 | N/A | INTERVENTION |
| 21 | A082101 | ALLIANCE | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | Multimodality Therapy with Immunotherapy in Stage I-IIIA Pleural Mesothelioma | II | 4/26 | N/A | INTERVENTION |
| 22 | A091903 | ALLIANCE | NCTN | Skin Cancer | Active | A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma | II | 63/99 | N/A | INTERVENTION |
| 23 | A092105 | ALLIANCE | NCTN | Head and Neck Cancer | Active | Randomized Phase 2 Study of Nivolumab and Ipilimumab with or Without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy | II | 11/50 | N/A | INTERVENTION |
| 24 | AOST2032 | COG | NCTN | Bone Cancer | Temporarily Closed to Accrual | A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma | II/III | 10/528 | N/A | INTERVENTION |
| 25 | CCTG-PR26 | CCTG | NCTN | Male Reproductive System Cancer | Active | A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH) | III | 0/830 | N/A | INTERVENTION |
| 26 | DCP-001 | DCP | NCORP | Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Solid Tumor | Active | Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) | Other | N/A | N/A | OTHER |
| 27 | EA1211 | ECOG-ACRIN | NCTN | Breast Cancer | Active | Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT Trial | II | 178/235 | N/A | INTERVENTION |
| 28 | EA2174 | ECOG-ACRIN | NCTN | Gastrointestinal Cancer | Temporarily Closed to Accrual | A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma | II/III | 275/278 | N/A | INTERVENTION |
| 29 | EA2192 | ECOG-ACRIN | NCTN | Gastrointestinal Cancer | Active | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | II | 88/152 | N/A | INTERVENTION |
| 30 | EA4232 | ECOG-ACRIN | NCTN | Lymphoma | Active | A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT) | III | 0/294 | N/A | INTERVENTION |
| 31 | EA6141 | ECOG-ACRIN | NCTN | Skin Cancer | Active | Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma | II/III | 543/601 | N/A | INTERVENTION |
| 32 | EA8134 | ECOG-ACRIN | NCTN | Male Reproductive System Cancer | Active | InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) | III | 115/200 | N/A | INTERVENTION |
| 33 | EA8192 | ECOG-ACRIN | NCTN | Urothelial/ Bladder Cancer | Active | A Phase II/III Trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy | II/III | 78/249 | N/A | INTERVENTION |
| 34 | EA8212 | ECOG-ACRIN | NCTN | Urothelial/ Bladder Cancer | Active | A Randomized Phase III Trial of Intravesical BCG VeRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE) | III | 764/870 | N/A | INTERVENTION |
| 35 | EA9213 | ECOG-ACRIN | NCTN | Leukemia | Active | A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) | II | 7/20 | N/A | INTERVENTION |
| 36 | EAA173 | ECOG-ACRIN | NCTN | Myeloma | Active | Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) | III | 217/288 | N/A | INTERVENTION |
| 37 | EAY191 | ECOG-ACRIN | NCTN | Lymphoma;Solid Tumor | Active | Molecular Analysis for Combination Therapy Choice (ComboMATCH) | Other | N/A | 361 | SCREENING |
| 38 | EAY191-N5 | NRG | NCTN | Bone Cancer;CNS Cancer (Primary tumor);Endocrine Cancer;Female Reproductive System Cancer;Gastrointestinal Cancer;Germ Cell Cancer;Head and Neck Cancer;Kidney Cancer;Lung, Mediastinal, and Pleural Cancer;Male Reproductive System Cancer;Miscellaneous and Metastatic Cancer;Skin Cancer;Soft Tissue Cancer/Sarcoma;Solid Tumor;Urothelial/ Bladder Cancer | Active | A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial | II | 10/70 | N/A | INTERVENTION |
| 39 | NRG-BR008 | NRG | NCTN | Breast Cancer | Active | A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO) | III | 81/1300 | N/A | INTERVENTION |
| 40 | NRG-CC011 | NRG | NCORP | Breast Cancer | Active | Cognitive Training For Cancer Related Cognitive Impairment In Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial | III | 215/386 | N/A | INTERVENTION |
| 41 | NRG-GU012 | NRG | NCTN | Kidney Cancer | Active | Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) | II | 54/240 | N/A | INTERVENTION |
| 42 | NRG-GY022 | NRG | NCTN | Solid Tumor | Active | Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin | I | 293/350 | N/A | INTERVENTION |
| 43 | NRG-GY032 | NRG | NCTN | Female Reproductive System Cancer | Active | A Phase II Study of Tailored Adjuvant Therapy in Pole-Mutated and p53-Wildtype/NSMP Early-Stage Endometrial Cancer (RAINBO BLUE & TAPER) | II | 4/395 | N/A | INTERVENTION |
| 44 | PBTC-061 | PBTC | MISCELLANEOUS | CNS Cancer (Primary tumor) | Active | Phase 2 Trial of G207 + 5 Gy Radiation for Children with High-Grade Gliomas | II | 0/35 | N/A | INTERVENTION |
| 45 | S1703 | SWOG | NCORP | Breast Cancer | Active | Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer | Other | 396/739 | 585 | SCREENING, INTERVENTION |
| 46 | S1933 | SWOG | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status | II | 43/47 | N/A | INTERVENTION |
| 47 | S2012 | SWOG | NCTN | Endocrine Cancer | Active | Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) | II/III | 89/189 | N/A | INTERVENTION |
| 48 | S2013 | SWOG | NCORP | N/A | Active | Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study | Other | N/A | N/A | OTHER |
| 49 | S2209 | SWOG | NCTN | Myeloma | Active | A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance | III | 72/510 | N/A | INTERVENTION |
| 50 | S2312 | SWOG | NCTN | Male Reproductive System Cancer | Active | A Phase III Study of Cabazitaxel with or Without Carboplatin in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature | III | 16/500 | N/A | INTERVENTION |